EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma

Kathryn R Tringale iD, Suzanne L Wolden iD, Dana L Casey iD, Brian H Kushner, Leo Luo, Neeta Pandit-Taskar, Mark Souweidane, Nai-Kong V Cheung, Shakeel Modak, Ellen M Basu, Kim Kramer

Pediatric Blood & Cancer · 2023-02 · 70 (2)

DOI: 10.1002/pbc.30075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 09.11.2022. Verfasst von Kathryn R Tringale und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Neuroblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In high‐risk neuroblastoma, multimodality therapy including craniospinal irradiation (CSI) is effective for central nervous system (CNS) relapse. Management of post‐CSI CNS relapse is not clearly defined. Procedure Pediatric patients with neuroblastoma treated with CSI between 2000 and 2019 were identified. Treatment of initial CNS disease (e.g., CSI, intraventricular compartmental radioimmunotherapy [cRIT] with 131 I‐monoclonal antibodies targeting GD2 or B7H3) and management of post‐CSI CNS relapse (“second CNS relapse”) were characterized. Cox proportional hazards models to evaluate factors associated with third CNS relapse and overall survival (OS) were used.

Results

Of 128 patients (65% male, median age 4 years), 19 (15%) received CSI with protons and 115 (90%) had a boost. Most (103, 81%) received cRIT, associated with improved OS (hazard ratio [HR] 0.3, 95% confidence interval [CI]: 0.1–0.5, p < .001). Forty (31%) developed a second CNS relapse, associated with worse OS (1‐year OS 32.5%, 95% CI: 19‐47; HR 3.8; 95% CI: 2.4–6.0, p < .001), and more likely if the leptomeninges were initially involved (HR 2.5, 95% CI: 1.3–4.9, p = .006). Median time to second CNS relapse was 6.8 months and 51% occurred outside the CSI boost field. Twenty‐five (63%) patients underwent reirradiation, most peri‐operatively (18, 45%) with focal hypofractionation. Eight (20%) patients with second CNS relapse received cRIT, associated with improved OS (HR 0.1; 95% CI: 0.1–0.4, p < .001).

Conclusions

CNS relapse after CSI for neuroblastoma portends a poor prognosis. Surgery with hypofractionated radiotherapy was the most common treatment. Acknowledging the potential for selection bias, receipt of cRIT both at first and second CNS relapse was associated with improved survival. This finding necessitates further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalNeuroblastomaChildHumansMaleChild, PreschoolFemaleCombined Modality TherapyRadioimmunotherapyCentral Nervous System

Stichwörter der Autor:innen

craniospinal irradiationintraventricular compartmental radioimmunotherapyneuroblastomapediatric cancersradiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Kathryn R Tringale, Suzanne L Wolden, Dana L Casey

Zitieren

APA

Tringale, K. R., Wolden, S. L., Casey, D. L., Kushner, B. H., Luo, L., Pandit-Taskar, N., Souweidane, M., Cheung, N. V., Modak, S., Basu, E. M., & Kramer, K. (2023). Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma. Pediatric Blood & Cancer, 70(2). https://doi.org/10.1002/pbc.30075

Vancouver

Tringale KR, Wolden SL, Casey DL, Kushner BH, Luo L, Pandit-Taskar N, et al. Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma. Pediatric Blood & Cancer. 2023;70(2). doi:10.1002/pbc.30075

BibTeX
@article{Tringale2023,
  author = {Tringale, Kathryn R and Wolden, Suzanne L and Casey, Dana L and Kushner, Brian H and Luo, Leo and Pandit-Taskar, Neeta and Souweidane, Mark and Cheung, Nai-Kong V and Modak, Shakeel and Basu, Ellen M and Kramer, Kim},
  title = {Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  volume = {70},
  number = {2},
  doi = {10.1002/pbc.30075}
}
Kostenlos starten →